SYNTEX WILL RUN NAPROSYN CORRECTIVE ADS IN 18 MEDICAL JOURNALS AND ON "LIFETIME" TV IN COURT-FILED CONSENT DECREE TO HALT ARTHROPROTECTIVE CLAIMS